Beijing, Shanghai & Boston, Oct. 29, 2022 — Jacobio Pharma (1167.HK) has received IND (Investigational New Drug) approval of its self-developed global first-in-class drug Aurora A inhibitor JAB-2485 from the Center for Drug Evaluation (the “CDE”) of China. Jacobio plans to initiate a Phase I/IIa clinical trial in patients with advanced solid tumors in the China.
JAB-2485 is a highly selective small molecule Aurora A inhibitor. JAB-2485 can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumor growth. At present, there is no commercialized Aurora A inhibitor globally. Jacobio's self-developed JAB-2485 is the second Aurora A inhibitor enter into clinical stage in China, and third in the United States.
JAB-2485 has good anti-tumor activity. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple negative breast cancer.
Relevant studies have shown that Aurora A and SHP2 inhibitors may be one of the therapies to solve the drug resistance of KRAS G12C inhibitors, Jacobio has these three self-developed drugs in clinical stage, including SHP2 inhibitors (JAB-3312 and JAB-3068), Aurora A inhibitor (JAB-2485) and KRAS G12C inhibitors (JAB-21822), which has potential to provide more combination therapies to patients.
Jacobio is committed to providing more products and solutions to people's health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The company's R&D centers are located in Beijing, Shanghai and Boston, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors. Please visit www.jacobiopharma.com for more information.